Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Analyst upgrades, led by Goldman Sachs Buy rating on Palantirs sovereign-AI and customized-software opportunities, are a key focus alongside the stocks breakout to new highs. Bulls celebrate the momentum and speculate about a short squeeze, while skeptics point to the stretched valuation and risk of a pullback.

Modernas rally is being linked to Nasdaq-100 reentry and expected index-fund buying, alongside an NIH-backed effort to accelerate personalized cancer vaccines that traders see as supportive of its oncology program. Bulls point to the demand and cancer-vaccine prospects, while bears argue the move is detached from fundamentals and could fade after index-related buying subsides.

NVAXs sharp rally is being linked to broader vaccine-sector strength after an NIH cancer-vaccine initiative lifted Moderna, while traders also focused on EU authorization of Sanofis Phase 3 COVID-flu combination trial and its potential milestone for Novavax. Many expect short-covering to amplify the move, but others question its durability and dismiss speculation about a Russian outbreak as unverified.

Microsofts launch of Microsoft-Decision-1, a specialized AI model for fast automated decisions, is drawing attention as shares push toward a record close. Traders are celebrating the breakout and AI momentum, while skeptics question whether the rally is justified and warn of an overextended valuation.

SpaceXs planned acquisition of low-band spectrum has intensified concerns that Starlink could become a stronger competitor to AST SpaceMobile, contributing to a sharp selloff. Traders are divided: bears see a threat to ASTSs business, while bulls argue its carrier-partner model and access to operators spectrum remain differentiators; CEO Abel Avellan pushed back on the competitive concerns.

Snowflakes stronger-than-expected quarterly results and raised outlook, with AI demand cited as boosting data-platform consumption, drove a sharp rally and continued focus on the stock. Traders are divided between expecting further gains and warning that the valuation is stretched, with some pointing to profit-taking after the earnings surge.

Mosaic is drawing attention after a steep selloff to multi-year lows, with traders pointing to weak results, elevated sulfur costs, and the withdrawal of phosphate production guidance as pressures on its outlook. Some see the depressed valuation as a buying opportunity, while others fear further losses and question the companys ability to maintain its dividend.

Mercks partnership with Moderna on a personalized mRNA cancer vaccine is drawing attention after the Phase 3 melanoma trial met recurrence-free and distant metastasis-free survival endpoints alongside Keytruda. Traders are weighing the pipeline upside and potential to strengthen Mercks oncology franchise against uncertainty about the full data, overall-survival benefit, and how much optimism is already reflected in the shares.

Hims & Hers shares surged as traders revisited the potential peptide opportunity, including speculation about regulatory access, alongside a broader rally in biotech and pharma names. Bulls viewed the move as a possible breakout or short-covering rally, while skeptics saw another short-lived pop in the stocks prolonged trading range.

Ondas reported surge in defense orders and expanding backlog are drawing attention, but the shares have continued to weaken despite the positive news. Traders are split between viewing the contracts as evidence of growing demand for its drone and defense systems and worrying about dilution, heavy short interest, and whether orders will convert into revenue.